Monopar Therapeutics (MNPR) Share-based Compensation Growth (3y) (2020 - 2025)
Monopar Therapeutics (MNPR) Share-based Compensation Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -50.27% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - | -120.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.70% |
| Sep 30, 2025 | 247.24% |
| Jun 30, 2025 | 286.34% |
| Mar 31, 2025 | 169.65% |
| Dec 31, 2024 | 134.49% |
| Sep 30, 2024 | -28.09% |
| Jun 30, 2024 | -20.29% |
| Mar 31, 2024 | -3.72% |
| Dec 31, 2023 | -75.97% |
| Sep 30, 2023 | -7.29% |
| Jun 30, 2023 | -6.00% |
| Mar 31, 2023 | -12.95% |
| Dec 31, 2022 | 12.43% |
| Sep 30, 2022 | -5.44% |
| Jun 30, 2022 | -16.02% |
| Mar 31, 2022 | 28.83% |
| Dec 31, 2021 | 14.55% |
| Sep 30, 2021 | 61.40% |
| Jun 30, 2021 | 59.23% |
| Mar 31, 2021 | 47.60% |